DOCSLIB.ORG

50075 HEM D Fata Ao Oyo 50 100 150 200 Time Post- Injection (Hrs ) US 9 ,850 , 297 B2 Page 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
50075 HEM D Fata Ao Oyo 50 100 150 200 Time Post- Injection (Hrs ) US 9 ,850 , 297 B2 Page 2 |HAO WANATATALITATUS009850297B2 DE LA MULT MAI MULT (12 ) United States Patent (10 ) Patent No. : US 9 ,850 , 297 B2 Majeti et al. ( 45) Date of Patent: Dec . 26 , 2017 ( 54 ) SECRETED FRIZZLE - RELATED PROTEIN 5 C12N 15 / 10 ( 2006 .01 ) (SFRP5 ) BINDING PROTEINS C12N 15 / 11 ( 2006 .01 ) A61K 39 / 00 (2006 .01 ) (71 ) Applicant: AMGEN INC . , Thousand Oaks , CA (52 ) U . S . CI. (US ) CPC .. C07K 16 / 18 (2013 .01 ) ; A61K 2039/ 505 (72 ) Inventors : Jiangwen Majeti , Palo Alto , CA ( US) ; ( 2013. 01 ) ; CO7K 2317 /14 (2013 . 01 ) ; CO7K YuMei Xiong, Palo Alto , CA (US ) ; 2317 /51 ( 2013 . 01 ) ; CO7K 2317 / 515 (2013 . 01 ) ; Wen -Chen Yeh , Belmont, CA (US ) ; CO7K 2317 / 565 (2013 .01 ) ; CO7K 2317 /76 Alykhan S . Motani, San Francisco , CA ( 2013 .01 ) ; CO7K 2317/ 92 ( 2013 .01 ) (US ) ; Yang Li, Mountain View , CA (58 ) Field of Classification Search (US ) None See application file for complete search history . (73 ) Assignee : Amgen Inc ., Thousand Oaks , CA (US ) (56 ) References Cited ( * ) Notice : Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U . S . C . 154 (b ) by 105 days . PUBLICATIONS MacCallum et al. , Antibody -antigen interactions: contact analysis (21 ) Appl. No .: 14 / 776 , 012 and binding site topography, J . Mol. Biol. 262: 732 -745 , 1996 . * Lamminmaki et al. , Chrystal structure of a recombinant anti (22 ) PCT Filed : Mar. 14 , 2014 estradiol Fab fragment in complex with the 17beta -estradiol , J . Blol . Chem . 276 : 36687 - 94 , 2001 . * ( 86 ) PCT No . : PCT/ US2014 /029015 Chen et al ., Enahncement and destruction of antibody function by somatic mutation : unequal occurrence is controlled by V gene $ 371 ( C ) ( 1 ) , combinatorial associations, EMBO J. , 14 ( 12 ) : 2784 -2794 , 1995 . * Sep . 14 , 2015 Blumenthal et al. ; Blood , American society of Hematology ; 2006 ; 108 : 3 ; 965 - 973 . ( 87) PCT Pub . No. : WO2014 /144553 (Continued ) PCT Pub . Date : Sep . 18 , 2014 Primary Examiner - Claire Kaufman (65 ) Prior Publication Data US 2016 /0024196 A1 Jan . 28 , 2016 (57 ) ABSTRACT Methods of treating metabolic diseases and disorders using Related U . S . Application Data an antigen binding protein specific for the SFRP5 polypep (60 ) Provisional application No . 61 / 799, 619 , filed on Mar. tide are provided . In various embodiments the metabolic 15 , 2013 . disease or disorder is type 2 diabetes, obesity , dyslipidemia elevated glucose levels , elevated insulin levels and diabetic (51 ) Int . Cl. nephropathy. COZK 16 / 18 (2006 .01 ) C12N 5 / 10 ( 2006 .01 ) 11 Claims, 16 Drawing Sheets 2000 , A 24C18 . 3 ? 12E6 . 2 mAb,ug/ml A14 A 24P2 . 2 50075 HEM D Fata Ao OyO 50 100 150 200 Time post- injection (hrs ) US 9 ,850 , 297 B2 Page 2 (56 ) References Cited PUBLICATIONS He, et al ., Science ; A member of the Frizzled protein family mediating axis induction by Wnt -5A ; 1997 ; 275 : 1652 - 1654 . International Search Report for International application No . PCT/ US2014 /029015 , dated Aug . 5 , 2014 . Li et al . ; Genes & Development; 2008 ; Sfrp5 coordinates foregut specification and morphogenesis by antagonizing both canonical and non -canonical Wnt11 signaling ; 22 : 21 ; 3050 - 3063 . Maury et al . ; Molecular and Cellular Endocrinology ; Elsevier Ireland ; 2010 ; 314 : 1 - 16 . Mori et al. ; J Clinical Investigation ; Secreted frizzled - related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition ; 2012 ; 122 : 7 ; 2405 - 2415 . Oh et al .; WNT fans the flames in obesity ; Science ; 2010 ; 329 : 397 - 398 . Ouchi et al. , Science ; Supporting online material for Sfrp5 is an anti - inflammatory adipokine that modulates metabolic dysfunction in obesity ; 2010 ; 329 : 1 - 18 . Rauch et al ., J Clinical Invest .; Lighting the fat furnace without SFRP5 ; 2012 ; 122 : 7 ; 2349 - 2352 . * cited by examiner U . S . Patent Dec . 26 , 2017 Sheet 1 of 16 US 9 ,850 , 297 B2 Figure 1 • rhwnt- 3a OrhWnt- 3a + rhsFRP5 (6ug /ml ) A Vehicle 60 ,000 RelativeLucunits 2 ,000 0 , 000 0 __ . .. 2 -04 20 1 2 3 4 Log (ng / ml ) B rmSFRP5 -hemiFc 40000 W 0 ug /ml ? 0 . 0067 ug/ ml 30000 0 . 02 ug /ml AbsoluteLucunits(cps) XX 0 . 061 ug/ ml 20000 VZ 0 . 185 ug /ml 10.55 ug /ml 10000 1 .67 ug /ml UIIIIIIIIIIZ WITHIN HHH 3 5 ug /ml OPTI- MEM only rmWnt- 3a Treatment group U . S . Patent Dec . 26 , 2017 Sheet 2 of 16 US 9 ,850 , 297 B2 . + + . Neg. -. + . .- +. Ab-111220 . - . 1 1 20ugimiMABw/sfrp5+Wnt-3a . ZOLI 1 Bing3 . Ab-s 10H . Bin#2 Ab-5 .. A5-19 24P2 60ugimiMABwisfrp5+Wnt-3a Ab-1518 2019 Ab-14 Bin#1 . 1403 AbgA5-10 360ug/mlMABonly+Wnt-3a Ab-2 . 1614 . wnt-3a+Abri sfrp5 . NOMABadded . only . cells Figure2 . the on one Thousands ) cps( Units Luc Average U . S . Patent Dec . 26 , 2017 Sheet 3 of 16 US 9 ,850 , 297 B2 168h 96h 72h 24C18.3 20200 blood collection 24P22 .212E6 n=3foreachtimepoint 48h € 160 24h 100 hours SFRP5Ab 01h3h6h i.pdosing VVVV Figure3 )ugimi ( mAb A ? U . S . Patent Dec . 26 , 2017 Sheet 4 of 16 US 9 ,850 , 297 B2 Figure 4 A 8007 . IgG Control F anti- SFRP5 24P2. 2 anti- SFRP5 12E6 . 2 Bloodglucose(mg/dl) anti- SFRP5 24C18 . 3 À AEanti- SFRP5 1702 . 1 zl 60 min o IgG Control 30mpk p . anti- SFRP5 24P2. 2 30mpk A anti- SFRP5 12E6 . 2 30mpk Glucose(ml/dl) 6 anti -SFRP5 24C18 . 3 30mpk C- - - - - - - anti - SFRP5 1702. 1 30mpk * min U . S . Patent Dec . 26 , 2017 Sheet 5 of 16 US 9 ,850 , 297 B2 Figure 5 Fasting blood glucose over time o IgG Control anti - SFRP5 24P2 . 2 glucose,mg/dL A anti- SFRP5 12E6 . 2 - * * Z anti- SFRP5 24C18 . 3 HIZINIZ* *INUN anti- SFRP5 1702 . 1 IT MMMM T7I7/IINIA baseline WK1 WK2' WK3 WK4 Fasting serum Insulin = * o IgG Control = *TWITTTTTTTT anti - SFRP5 24P2. 2 A anti- SFRP5 12E6 . 2 Z anti - SFRP5 24C18 . 3 ng/dl - anti - SFRP5 1702. 1 ?????????? VIINIL W baselineTULO VILTIZO WK2 WK4 U . S . Patent Dec . 26 , 2017 Sheet 6 of 16 US 9 ,850 , 297 B2 Figure 5 (continued ) riguas continuesBody Weight O gG Control anti - SFRP5 24P2. 2 W anti - SFRP5 12E6 . 2 Bodyweight(g) 2 anti- SFRP5 24C18 . 3 ölö | anti- SFRP5 1702 . 1 ö ç ZITO WK1 WK2 ZIIIIIIIIIIIIZA, Fasting triglycerides O IgG Control w anti- SFRP5 24P2 . 2 anti- SFRP5 12E6 . 2 anti - SFRP5 24C18 . 3 Vioww anti- SFRP5 1702. 1 WINT KUL ww WIMMILTITULO WK1 WK4MUNIKA osobaseline U . S . Patent Dec . 26 , 2017 Sheet 7 of 16 US 9 ,850 , 297 B2 24P2.2SFRP5anti- anti-SFRP512E6.2 anti-SFRP524C18.3 anti-SFRP51702.1 IgGControl o ? * * * C-peptide Terminalfastingserum Figure6 15000, 5000 pmol10000 , peptide- C U . S . Patent Dec . 26 , 2017 Sheet 8 of 16 US 9 ,850 , 297 B2 oemptyvector oemptyvector SFRP5ASFRP5 BSFRP5 * * * s * * WK6 * * * Timepost-injection(min) +a CO- ©153060 WK4 . ---- WK2 OL ? ? ? ? baseline w dl/ mg , glucose blood o ,weightg body Oemptyvector oemptyvector BSFRP5 ESERP5 * -- -- * Timepost-injection(min) * - Timepost-injection(min) --- uö153060 - ©153060 --- 7Figure OLT cpFRES/bw '?so?n 6 pooja dlo/ mg ,glucose blood U . S . Patent Dec . 26 , 2017 Sheet 9 of 16 US 9 ,850 , 297 B2 oemptyvector ESFRP5 * * * * WK6 WH4 SFRP5emptyvector WK2 8 6 8 9 baseline 15000, 000 5000 TI mL/ ng , insulin I units arbitrary vectorempty vectoroempty SFRP5 ESFRP5 o ES * * * - -0- WK6 injection(min)Timepost- .. o204060 WK4 * ---- 1 * continued)Figure7( WK2 baseline de site ce ?i ? w pow ' ?soon 6 pooja dl/ mg , glucose blood USU . S . PatentPatent maisonDec . 26 , 2017 Sheet 10 of 16 US 9 ,850 ,297 B2 emptyvector SFRP5 * * SFRP5vectorempty baseline2WK 400007 30000 20000 ö õ units arbitrary g , weight body emptyvector ASFRP5 oemptyvector SFRP5 * :*00 ** Timepost-injection(min) Timepost-injection(min) ----- ó204060 * KIO ** oó204060 *& Q ** Figure8 ? ? 200- D dl/ mg , glucose blood dl /mg , glucose blood U . S . Patent Dec . 26 , 2017 Sheet 11 of 16 US 9 ,850 ,297 B2 Oemptyvector SFRP5 II II * 1 IT * baseline2WK * SFRP5 ?? 0 vectorempty mL/ ng , insulin I pmol , proinsulin Oemptyvector SFRP5 * * * * baseline2WK SFRP5 Figure8(continued) vectorempty § § ñ ñ § 5000, 00 . m dl/ mg , glucose blood O pmol , insulin U . S . Patent Dec . 26 , 2017 Sheet 12 of 16 US 9 ,850 ,297 B2 anti-SFRP5mAb(ug/ml) ood -0.512 60ug/ml w/noz6.7ug/ml anti-SFRP5mAb 52.2ug/ml N0.74ug/ml OOug/ml 4x104, 104 ) CPS ( Luminescence RETTITUNTER MMMMMM 10 24P2.2 VM . rmSFRP5(ug/ml) recombinantmouseSFRP5(ug/ml) 3 7777777777777777777 10.011 LETTMT MTTEITIM ????? DUNIIHINNAPITIA 1090.0110 12E6.2 1x1004 5x105. W ) CPS( Luminescence 1 6 .. TITUTI H - - " - - - - - - - - - - - - - . - 09 12. 19 2 . no 50100150200 rmWNT3a(ng/ml) 24C18.3 JUL ( O M XXXXXXXXXX * WWW 09 4x104, x104 2x104 1x104 Figure9 -c0 2x105 oderno 11) CPS( Luminescence ) CPS( Luminescence atent Dec . 26 , 2017 Sheet 13 of 16 US 9 ,850 ,297 B2 12E6.2 A24C18.3 A24P2.2 5 Timepost-injection(hrs) KA 050100150200 HH Figure10 19946 š iš500 ml/ ug , mAb U . S . Patent Dec. 26 , 2017 Sheet 14 of 16 US 9 ,850 ,297 B2 24C18.3 24C18.3 IgGControl A12E6.2 V24P2.2 IgGControl A12E6.2 #24P2.2 WK4 Timepost-injection(min) ó153060 WK2 . WK1 o og dl/ mg , glucose blood o ,gweight body baseline 24C18.324C18.3 24C18.3 24P2.2 IgGControl 12E6.2A V24P2.2 IgGControl A12E6.2 TO Timepost-injection(min) Timepost-injection(min) ö153060 to153060 11Figure § 8 8 8 8 x dl/ mg , glucose blood 0 dl/ mg ,glucose blood U . S . Patent Dec . 26 , 2017 Sheet 15 of 16 US 9 ,850 ,297 B2 Figure 11 (continued ) bloodglucose,mg/dlm IgG Control 24C18 . 3 lei TOIR A 12E6 . 2 * * * 24P2 . 2 * * * * baseline 1WK 2WK7 4 WK 71 on insulin/proinsulin NW– IgGControl 24C18 .3 12E6 .2 24P2 .2 * * * * * * * * * * * C-peptideproinsulino/ IgGControl 24C18 .312E6 .24 24P2 .
Load more

Recommended publications
  • Hyperactivated Wnt-Β-Catenin Signaling in the Absence of Sfrp1 and Sfrp5 Disrupts Trophoblast Differentiation Through Repressio
    Bao et al. BMC Biology (2020) 18:151 https://doi.org/10.1186/s12915-020-00883-4 RESEARCH ARTICLE Open Access Hyperactivated Wnt-β-catenin signaling in the absence of sFRP1 and sFRP5 disrupts trophoblast differentiation through repression of Ascl2 Haili Bao1,2,3†, Dong Liu2†, Yingchun Xu2, Yang Sun2, Change Mu2, Yongqin Yu2, Chunping Wang2, Qian Han2, Sanmei Liu2, Han Cai1,2, Fan Liu2, Shuangbo Kong1,2, Wenbo Deng1,2, Bin Cao1,2, Haibin Wang1,2*, Qiang Wang3,4* and Jinhua Lu1,2* Abstract Background: Wnt signaling is a critical determinant for the maintenance and differentiation of stem/progenitor cells, including trophoblast stem cells during placental development. Hyperactivation of Wnt signaling has been shown to be associated with human trophoblast diseases. However, little is known about the impact and underlying mechanisms of excessive Wnt signaling during placental trophoblast development. Results: In the present work, we observed that two inhibitors of Wnt signaling, secreted frizzled-related proteins 1 and 5 (Sfrp1 and Sfrp5), are highly expressed in the extraembryonic trophoblast suggesting possible roles in early placental development. Sfrp1 and Sfrp5 double knockout mice exhibited disturbed trophoblast differentiation in the placental ectoplacental cone (EPC), which contains the precursors of trophoblast giant cells (TGCs) and spongiotrophoblast cells. In addition, we employed mouse models expressing a truncated β-catenin with exon 3 deletion globally and trophoblast-specifically, as well as trophoblast stem cell lines, and unraveled that hyperactivation of canonical Wnt pathway exhausted the trophoblast precursor cells in the EPC, resulting in the overabundance of giant cells at the expense of spongiotrophoblast cells.
    [Show full text]
  • Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer
    life Article Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer Dehua Liu 1 , Chenyu Sun 2 , Nahyun Kim 2 , Chandur Bhan 2, John Pocholo Whitaker Tuason 2, Yue Chen 3, Shaodi Ma 4, Yuting Huang 5 , Ce Cheng 6,7, Qin Zhou 8 and Kaiguang Zhang 1,* 1 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; [email protected] 2 Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, IL 60657, USA; [email protected] (C.S.); [email protected] (N.K.); [email protected] (C.B.); [email protected] (J.P.W.T.) 3 Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, Hefei 230032, China; [email protected] 4 Department of Epidemiology and Health Statistics, School of Public Health Anhui Medical University, Hefei 230032, China; [email protected] 5 University of Maryland Medical Center Midtown Campus, Baltimore, MD 21201, USA; [email protected] 6 The University of Arizona College of Medicine, Banner University Medical Center at South Campus, Tucson, AZ 85724, USA; [email protected] 7 Banner-University Medical Center South, Tucson, AZ 85713, USA 8 Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA; [email protected] * Correspondence: [email protected]; Tel.: +86-138-5517-0097 Citation: Liu, D.; Sun, C.; Kim, N.; Abstract: Gastric cancer (GC) is the fifth most common cancer globally. Secreted frizzled-related Bhan, C.; Tuason, J.P.W.; Chen, Y.; Ma, proteins (SFRP) are important elements associated with the Wnt signaling pathway, and its dysregu- S.; Huang, Y.; Cheng, C.; Zhou, Q.; lated expression is found in multiple cancers.
    [Show full text]
  • Cholesterol 25-Hydroxylase on Chromosome 10Q Is a Susceptibility Gene for Sporadic Alzheimer’S Disease
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2005 Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer’s disease Papassotiropoulos, A ; Lambert, J C ; Wavrant-De Vrièze, F ; Wollmer, M A ; von der Kammer, H ; Streffer, J R ; Maddalena, A ; Huynh, K D ; Wolleb, S ; Lütjohann, D ; Schneider, B;Thal,DR Grimaldi, L M E ; Tsolaki, M ; Kapaki, E ; Ravid, R ; Konietzko, U ; Hegi, T ; Pasch, T ; Jung, H ; Braak, H ; Amouyel, P ; Rogaev, E I ; Hardy, J ; Hock, C ; Nitsch, R M Abstract: Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by beta- amyloid (A beta) plaques, neurofibrillary tangles and the degeneration of specifically vulnerable brain neurons. We observed high expression of the cholesterol 25-hydroxylase (CH25H) gene in specifically vulnerable brain regions of AD patients. CH25H maps to a region within 10q23 that has been previ- ously linked to sporadic AD. Sequencing of the 5’ region of CH25H revealed three common haplotypes, CH25Hchi2, CH25Hchi3 and CH25Hchi4; CSF levels of the cholesterol precursor lathosterol were higher in carriers of the CH25Hchi4 haplotype. In 1,282 patients with AD and 1,312 healthy control subjects from five independent populations, a common variation in the vicinity of CH25H was significantly associated with the risk for sporadic AD (p = 0.006). Quantitative neuropathology of brains from elderly non- demented subjects showed brain A beta deposits in carriers of CH25Hchi4 and CH25Hchi3 haplotypes, whereas no A beta deposits were present in CH25Hchi2 carriers.
    [Show full text]
  • An RNA-Seq-Based Resource for Pain and Sensory Neuroscience Research
    bioRxiv preprint doi: https://doi.org/10.1101/165431; this version posted October 13, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Comparative transcriptome profiling of the human and mouse dorsal root ganglia: An RNA-seq-based resource for pain and sensory neuroscience research Short Title: Human and mouse DRG comparative transcriptomics Pradipta Ray 1, 2 #, Andrew Torck 1 , Lilyana Quigley 1, Andi Wangzhou 1, Matthew Neiman 1, Chandranshu Rao 1, Tiffany Lam 1, Ji-Young Kim 1, Tae Hoon Kim 2, Michael Q. Zhang 2, Gregory Dussor 1 and Theodore J. Price 1, # 1 The University of Texas at Dallas, School of Behavioral and Brain Sciences 2 The University of Texas at Dallas, Department of Biological Sciences # Corresponding authors Theodore J Price Pradipta Ray School of Behavioral and Brain Sciences School of Behavioral and Brain Sciences The University of Texas at Dallas The University of Texas at Dallas BSB 14.102G BSB 10.608 800 W Campbell Rd 800 W Campbell Rd Richardson TX 75080 Richardson TX 75080 972-883-4311 972-883-7262 [email protected] [email protected] Number of pages: 27 Number of figures: 9 Number of tables: 8 Supplementary Figures: 4 Supplementary Files: 6 Word count: Abstract = 219; Introduction = 457; Discussion = 1094 Conflict of interest: The authors declare no conflicts of interest Patient anonymity and informed consent: Informed consent for human tissue sources were obtained by Anabios, Inc. (San Diego, CA). Human studies: This work was approved by The University of Texas at Dallas Institutional Review Board (MR 15-237).
    [Show full text]
  • 393LN V 393P 344SQ V 393P Probe Set Entrez Gene
    393LN v 393P 344SQ v 393P Entrez fold fold probe set Gene Gene Symbol Gene cluster Gene Title p-value change p-value change chemokine (C-C motif) ligand 21b /// chemokine (C-C motif) ligand 21a /// chemokine (C-C motif) ligand 21c 1419426_s_at 18829 /// Ccl21b /// Ccl2 1 - up 393 LN only (leucine) 0.0047 9.199837 0.45212 6.847887 nuclear factor of activated T-cells, cytoplasmic, calcineurin- 1447085_s_at 18018 Nfatc1 1 - up 393 LN only dependent 1 0.009048 12.065 0.13718 4.81 RIKEN cDNA 1453647_at 78668 9530059J11Rik1 - up 393 LN only 9530059J11 gene 0.002208 5.482897 0.27642 3.45171 transient receptor potential cation channel, subfamily 1457164_at 277328 Trpa1 1 - up 393 LN only A, member 1 0.000111 9.180344 0.01771 3.048114 regulating synaptic membrane 1422809_at 116838 Rims2 1 - up 393 LN only exocytosis 2 0.001891 8.560424 0.13159 2.980501 glial cell line derived neurotrophic factor family receptor alpha 1433716_x_at 14586 Gfra2 1 - up 393 LN only 2 0.006868 30.88736 0.01066 2.811211 1446936_at --- --- 1 - up 393 LN only --- 0.007695 6.373955 0.11733 2.480287 zinc finger protein 1438742_at 320683 Zfp629 1 - up 393 LN only 629 0.002644 5.231855 0.38124 2.377016 phospholipase A2, 1426019_at 18786 Plaa 1 - up 393 LN only activating protein 0.008657 6.2364 0.12336 2.262117 1445314_at 14009 Etv1 1 - up 393 LN only ets variant gene 1 0.007224 3.643646 0.36434 2.01989 ciliary rootlet coiled- 1427338_at 230872 Crocc 1 - up 393 LN only coil, rootletin 0.002482 7.783242 0.49977 1.794171 expressed sequence 1436585_at 99463 BB182297 1 - up 393
    [Show full text]
  • Transcript Profiling of Embryonic Gut Development in Wildtype and Ret-Deficient Mice
    bioRxiv preprint doi: https://doi.org/10.1101/730010; this version posted August 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Biological Sciences: Genetics and Developmental Biology The gastrointestinal development ‘parts list’: transcript profiling of embryonic gut development in wildtype and Ret-deficient mice Sumantra Chatterjee,1,2,* Priyanka Nandakumar,1,* Dallas R. Auer,1,2 Stacey B. Gabriel,3 Aravinda Chakravarti1,2+ 1Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 2Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY 10016; 3The Broad Institute, Cambridge, MA 02142, USA. *These authors contributed equally to the work ORCID IDs Sumantra Chatterjee: 0000-0002-5076-1698 Priyanka Nandakumar: 0000-0002-2332-6746 Dallas R. Auer: 0000-0003-4466-4135 Aravinda Chakravarti: 0000-0002-4264-2285 short title: Transcriptional profiles across mouse gut development Key words: Gut development, RNA-seq, Ret, non-autonomous cell effects +Send all correspondence to: Aravinda Chakravarti, Ph.D. Center for Human Genetics & Genomics New York University School of Medicine 435 East 30th Street, Room 802/3 New York, NY 10016 T: (212) 263-8023 E: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/730010; this version posted August 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The development of the gut from endodermal tissue to an organ with multiple distinct structures and functions occurs over a prolonged time during embryonic days E10.5- E14.5 in the mouse.
    [Show full text]
  • Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth
    Research Article: New Research Development Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth Jeremy S. Toma,1 Konstantina Karamboulas,1,ª Matthew J. Carr,1,2,ª Adelaida Kolaj,1,3 Scott A. Yuzwa,1 Neemat Mahmud,1,3 Mekayla A. Storer,1 David R. Kaplan,1,2,4 and Freda D. Miller1,2,3,4 https://doi.org/10.1523/ENEURO.0066-20.2020 1Program in Neurosciences and Mental Health, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada, 2Institute of Medical Sciences University of Toronto, Toronto, Ontario M5G 1A8, Canada, 3Department of Physiology, University of Toronto, Toronto, Ontario M5G 1A8, Canada, and 4Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1A8, Canada Abstract Peripheral nerves provide a supportive growth environment for developing and regenerating axons and are es- sential for maintenance and repair of many non-neural tissues. This capacity has largely been ascribed to paracrine factors secreted by nerve-resident Schwann cells. Here, we used single-cell transcriptional profiling to identify ligands made by different injured rodent nerve cell types and have combined this with cell-surface mass spectrometry to computationally model potential paracrine interactions with peripheral neurons. These analyses show that peripheral nerves make many ligands predicted to act on peripheral and CNS neurons, in- cluding known and previously uncharacterized ligands. While Schwann cells are an important ligand source within injured nerves, more than half of the predicted ligands are made by nerve-resident mesenchymal cells, including the endoneurial cells most closely associated with peripheral axons. At least three of these mesen- chymal ligands, ANGPT1, CCL11, and VEGFC, promote growth when locally applied on sympathetic axons.
    [Show full text]
  • Cytogenetics
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It presents structured review articles ("cards") on genes, leukaemias, solid tumours, cancer-prone diseases, more traditional review articles on these and also on surrounding topics ("deep insights"), case reports in hematology, and educational items in the various related topics for students in Medicine and in Sciences. Editorial correspondance Jean-Loup Huret Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France tel +33 5 49 44 45 46 or +33 5 49 45 47 67 [email protected] or [email protected] Staff Mohammad Ahmad, Mélanie Arsaban, Houa Delabrousse, Marie-Christine Jacquemot-Perbal, Maureen Labarussias, Vanessa Le Berre, Anne Malo, Catherine Morel-Pair, Laurent Rassinoux, Sylvie Yau Chun Wan - Senon, Alain Zasadzinski. Philippe Dessen is the Database Director, and Alain Bernheim the Chairman of the on-line version (Gustave Roussy Institute – Villejuif – France). The Atlas of Genetics and Cytogenetics in Oncology and Haematology (ISSN 1768-3262) is published 12 times a year by ARMGHM, a non profit organisation, and by the INstitute for Scientific and Technical Information of the French National Center for Scientific Research (INIST-CNRS) since 2008. The Atlas is hosted by INIST-CNRS (http://www.inist.fr) http://AtlasGeneticsOncology.org © ATLAS - ISSN 1768-3262 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues.
    [Show full text]
  • A Role for Sfrp5 in Adipocyte Biology and Obesity by Tyler C. Prestwich
    A Role for sFRP5 in Adipocyte Biology and Obesity by Tyler C. Prestwich A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cellular and Molecular Biology) in The University of Michigan 2008 Doctoral Committee: Professor Ormond A. MacDougald, Chair Professor Charles Burant Professor Eric R. Fearon Associate Professor Kenneth M. Cadigan Assistant Professor Peter C. Lucas Tyler C. Prestwich 2008 Table of Contents List of Figures iv Chapter I. Wnt/β-catenin Signaling in Adipogenesis and Metabolism 1 Summary 1 Introduction 1 Wnt Signaling Regulates Adipogenesis In Vitro and In Vivo 3 Wnt/β-catenin Signaling and Human Metabolic Disorders 6 Recent Advances in Wnt/β-catenin-Mediated Effects on Adipogenesis 7 Regulation of Mesenchymal Cell Fate 7 β-catenin as a Central Mechanism for Inhibiting Adipogenesis 9 Conclusions 10 II. A Role for sFRP5 in Adipocyte Biology and Obesity 18 Abstract 18 Introduction 19 Materials and Methods 21 Results 30 Expression and Localization of sFRP5 In Vitro and In Vivo 30 sFRP5 is Associated with Increasing Adiposity and Adipocyte Size 31 sFRP5Q27stop Mice Resist Diet-Induced Obesity and Display a Reduction in Fat Mass 32 sFRP5 Regulates Adipocyte Size During Obesity in a Tissue Autonomous Manner 34 Relative Expression of Adipocyte and Vasculature Markers in sFRP5Q27stop Mice 36 Metabolic Phenotype of Mice Harboring the sFRP5Q27stop Mutation 38 Integrin Signaling may Mediate sFRP5-Regulated Adipocyte Clustering 39 Discussion 42 III. Expanding the Scope of sFRP5 Function 61 Introduction 61 Materials and Methods 62 ii Results 64 Temperature Dependent Effects on Food Intake in sFRP5Q27stop Mice 64 µCT Analysis of Cortical and Trabecular Bone in sFRP5Q27stop Mice 65 Microarray Analysis of G-WAT from sFRP5Q27stop mice 66 Discussion 68 IV.
    [Show full text]
  • A New Strategy to Identify and Annotate Human RPE-Specific Gene Expression
    A New Strategy to Identify and Annotate Human RPE-Specific Gene Expression Judith C. Booij1, Jacoline B. ten Brink1, Sigrid M. A. Swagemakers2,3, Annemieke J. M. H. Verkerk2, Anke H. W. Essing1, Peter J. van der Spek2, Arthur A. B. Bergen1,4,5* 1 Department of Clinical and Molecular Ophthalmogenetics, Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands, 2 Department of Bioinformatics and Genetics, Erasmus Medical Center, Rotterdam, The Netherlands, 3 Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, The Netherlands, 4 Clinical Genetics Academic Medical Centre Amsterdam, University of Amsterdam, The Netherlands, 5 Department of Ophthalmology, Academic Medical Centre Amsterdam, University of Amsterdam, The Netherlands Abstract Background: To identify and functionally annotate cell type-specific gene expression in the human retinal pigment epithelium (RPE), a key tissue involved in age-related macular degeneration and retinitis pigmentosa. Methodology: RPE, photoreceptor and choroidal cells were isolated from selected freshly frozen healthy human donor eyes using laser microdissection. RNA isolation, amplification and hybridization to 44 k microarrays was carried out according to Agilent specifications. Bioinformatics was carried out using Rosetta Resolver, David and Ingenuity software. Principal Findings: Our previous 22 k analysis of the RPE transcriptome showed that the RPE has high levels of protein synthesis, strong energy demands, is exposed to high levels of oxidative stress and a variable degree of inflammation. We currently use a complementary new strategy aimed at the identification and functional annotation of RPE-specific expressed transcripts. This strategy takes advantage of the multilayered cellular structure of the retina and overcomes a number of limitations of previous studies.
    [Show full text]
  • Prediction of Human Disease Genes by Human-Mouse Conserved Coexpression Analysis
    Prediction of Human Disease Genes by Human-Mouse Conserved Coexpression Analysis Ugo Ala1., Rosario Michael Piro1., Elena Grassi1, Christian Damasco1, Lorenzo Silengo1, Martin Oti2, Paolo Provero1*, Ferdinando Di Cunto1* 1 Molecular Biotechnology Center, Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy, 2 Department of Human Genetics and Centre for Molecular and Biomolecular Informatics, University Medical Centre Nijmegen, Nijmegen, The Netherlands Abstract Background: Even in the post-genomic era, the identification of candidate genes within loci associated with human genetic diseases is a very demanding task, because the critical region may typically contain hundreds of positional candidates. Since genes implicated in similar phenotypes tend to share very similar expression profiles, high throughput gene expression data may represent a very important resource to identify the best candidates for sequencing. However, so far, gene coexpression has not been used very successfully to prioritize positional candidates. Methodology/Principal Findings: We show that it is possible to reliably identify disease-relevant relationships among genes from massive microarray datasets by concentrating only on genes sharing similar expression profiles in both human and mouse. Moreover, we show systematically that the integration of human-mouse conserved coexpression with a phenotype similarity map allows the efficient identification of disease genes in large genomic regions. Finally, using this approach on 850 OMIM loci characterized by an unknown molecular basis, we propose high-probability candidates for 81 genetic diseases. Conclusion: Our results demonstrate that conserved coexpression, even at the human-mouse phylogenetic distance, represents a very strong criterion to predict disease-relevant relationships among human genes. Citation: Ala U, Piro RM, Grassi E, Damasco C, Silengo L, et al.
    [Show full text]
  • Frequent Epigenetic Inactivation of SFRP Genes and Constitutive Activation of Wnt Signaling in Gastric Cancer
    Oncogene (2007) 26, 4699–4713 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer M Nojima1,8, H Suzuki1,2,8, M Toyota1,3,4, Y Watanabe5, R Maruyama1, S Sasaki1, Y Sasaki3, H Mita3, N Nishikawa6, K Yamaguchi6, K Hirata6, F Itoh5, T Tokino3, M Mori2, K Imai7 and Y Shinomura1 1First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan; 2Department of Public Health, Sapporo Medical University, Sapporo, Japan; 3Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan; 4PRESTO JST, Kawaguchi, Japan; 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, St Marianna University School of Medicine, Kasawaki, Japan; 6First Department of Surgery, Sapporo Medical University, Sapporo, Japan and 7Sapporo Medical University, Sapporo, Japan Activation of Wnt signaling has been implicated in gastric Introduction tumorigenesis, although mutations in APC (adenomatous polyposis coli), CTNNB1 (b-catenin) and AXIN are seen The two known Wnt signaling pathways play essential much less frequently in gastric cancer (GC) than in roles in the regulation of cell proliferation, patterning colorectal cancer. In the present study, we investigated and fate determination during normal developmen- the relationship between activation of Wnt signaling tal processes (Taketo, 2004). The canonical pathway and changes in the expression of secreted frizzled-related operates by stabilizing b-catenin, whereas the non- protein (SFRP) family genes in GC. We frequently canonical pathway does not require b-catenin signaling observed nuclear b-catenin accumulation (13/15; 87%) and controls cell movement during morphogenesis.
    [Show full text]